Biotech Earnings: Tenax, ADC, and Rapport Chart Paths for 2026 Growth
Key Takeaways
- Three distinct biotech players—Tenax, ADC Therapeutics, and Rapport—released 2025 year-end results, highlighting a shift from foundational clinical trials to commercial scaling and late-stage readouts.
- While Tenax advances its Phase 3 LEVEL trial, ADC Therapeutics focuses on ZYNLONTA’s market penetration and Rapport prepares for key data in epilepsy.
Mentioned
Key Intelligence
Key Facts
- 1ADC Therapeutics reported Q4 revenue of $23.06M, beating estimates by $0.77M.
- 2Tenax Therapeutics is prioritizing its Phase 3 LEVEL trial for TNX-201 in PH-HFpEF.
- 3Rapport Therapeutics is advancing RAP-219 for focal epilepsy using its proprietary RAP platform.
- 4ADC Therapeutics' Non-GAAP EPS for Q4 was -$0.05, reflecting improved cost management.
- 5All three companies provided updates on cash runways extending into key 2026 milestones.
| Company | |||
|---|---|---|---|
| Tenax Therapeutics | TNX-201 (Imatinib) | PH-HFpEF | Phase 3 |
| ADC Therapeutics | ZYNLONTA | DLBCL | Commercial |
| Rapport Therapeutics | RAP-219 | Focal Epilepsy | Phase 2 Ready |
Analysis
The Q4 2025 earnings cycle for mid-cap and small-cap biotech firms has underscored a critical transition period: the move from survival mode to execution mode. Tenax Therapeutics, ADC Therapeutics, and Rapport Therapeutics each represent different stages of this evolution. Tenax is currently navigating the high-stakes Phase 3 LEVEL trial for TNX-201, targeting pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). This condition remains one of the largest unmet needs in cardiovascular medicine, with no currently FDA-approved treatments specifically for this indication. The company’s focus on a proprietary formulation of imatinib aims to leverage a known mechanism in a novel, high-value setting.
ADC Therapeutics, conversely, is further along the commercial curve. Their flagship product, ZYNLONTA, continues to serve as the primary revenue driver while the company optimizes its cost structure and expands its ADC pipeline. The 2025 results reflect a stabilization of commercial operations, with Q4 revenue hitting $23.06 million, a slight beat over analyst expectations. This performance suggests that ZYNLONTA is carving out a sustainable niche in the diffuse large B-cell lymphoma (DLBCL) market, even as competition in the antibody-drug conjugate (ADC) space intensifies. The ADC sector has become white-hot in recent years, with massive M&A activity placing ADC Therapeutics in a strategic position as both a competitor and a potential partner.
Tenax Therapeutics, ADC Therapeutics, and Rapport Therapeutics each represent different stages of this evolution.
Rapport Therapeutics represents the frontier of precision neuroscience. By focusing on receptor-associated proteins (RAPs), Rapport is attempting to achieve a level of neuro-specificity that has eluded traditional small-molecule drugs. Their lead candidate, RAP-219, is a prime example of this targeted approach to the central nervous system. As they move through 2026, the market will be laser-focused on their ability to translate this platform into clinical efficacy without the systemic side effects that often plague CNS therapies. The company’s business update emphasizes the readiness of their pipeline for upcoming data readouts, which will be pivotal for their valuation in the coming year.
What to Watch
Across all three companies, a common theme is the disciplined allocation of capital toward de-risked or high-probability assets. For Tenax, this means prioritizing the LEVEL trial; for ADC, it involves maximizing the commercial lifecycle of ZYNLONTA while advancing next-generation ADCs; and for Rapport, it is about proving the RAP platform's viability in focal epilepsy. Investors should monitor the enrollment rates of the LEVEL trial and the quarterly sales trajectory of ZYNLONTA as key indicators of near-term momentum.
Looking forward, the biotech sector's health will depend on these companies' ability to meet clinical milestones while maintaining sufficient cash runways. The 2025 year-end reports suggest that these firms have successfully navigated the recent period of capital market volatility and are now positioned to deliver on their core scientific promises. The next 12 to 18 months will be transformative, potentially yielding new standards of care in cardiology, oncology, and neurology.
How we covered this story
Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled biotech-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |